Less Visibility On Long-Term Earnings Turn Investors Cautious On Indian Pharma; Government’s Apathy Adds To Concerns
This article was originally published in PharmAsia News
Singapore- and Hong Kong-based senior analysts, portfolio and hedge fund managers interviewed by PharmAsia News said the Indian market is undergoing a transition phase and shows limited upsides.
You may also be interested in...
With Over 348 Drugs In Proposed Pricing Policy, India Aims To Balance Industry Growth With Affordable Drugs
MUMBAI - After lying in hibernation for several years, policy proposals for tighter government control on pricing of the most used medicines in India is back in the headlines as the Department of Pharmaceuticals last week posted a comprehensive draft pricing policy and called for feedback from stakeholders before Nov. 30
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.